Biomira today announced positive preliminary survival data from a Phase 2 trial for Biomira’s BLP25 Liposome Vaccine, for the treatment of lung cancer (non-small cell lung cancer). The data showed that patients given the vaccine have survived an average of 30.6 months, compared with to 13.3 months for patients who did not receive the vaccine. Biomira is partnered with Merck KGaA on the development of BLP25. A Phase 3 study is going to begin early in 2006.
“The preliminary median survival data for the phase 2b study we have announced today underlines our confidence in the potential of L-BLP25 in the treatment of non-small cell lung cancer,” said Dr. Alex McPherson, M.D., Ph.D., President and CEO of Biomira. “We now look forward to the opportunity to demonstrate statistical significance for these promising results in a broader phase 3 program.”
